Peijia-backed Sutra Hemi-valve achieves first human implantation

Peijia Medical Limited announced that Sutra Medical, Inc., a company in which Peijia holds a strategic investment, successfully performed the first implantation in the first-in-man (FIM) clinical trial of its Sutra Hemi-valve Transcatheter Mitral Valve Repair System. The procedure took place at Waikato Hospital in New Zealand on an 83-year-old patient suffering from severe functional mitral regurgitation. The patient recovered well and was discharged on the third day.

Peijia Medical, which became the second largest shareholder of Sutra after its founding team following a stock purchase agreement on August 27, 2021, noted that Sutra Hemi-valve is designed as a posterior leaflet replacement. This innovative approach aims to restore mitral valve function by coapting with the native anterior leaflet, thereby eliminating mitral regurgitation without obstructing the left ventricular outflow tract.

The company advises shareholders and potential investors to exercise due care, as there is no guarantee that Sutra Hemi-valve will be successfully developed or ultimately marketed.